Last updated: June 2026. MOTS-c is a research-stage peptide, not an FDA-approved drug, and the human evidence behind it is still early and thin. Every factual claim below is footnoted to the paper or trial it came from, so you can go check it yourself instead of trusting my paraphrase.
Here’s a confession. I went looking for the MOTS-c dose the same way you probably did: typed it into a search bar, expected a number, the kind a pharmacist would print on a bottle label. What I got instead was a rabbit hole. And the honest report from that rabbit hole turns out to be more useful than the tidy chart I was hoping to hand you, so let’s walk through it together, the way I actually found it, dead ends included.
Think of this like trying to figure out the right dose of a recipe when all you have is: a note about how it worked on a much smaller animal, a story about someone’s body making a little of the ingredient on its own during a run, and one small trial of a completely different, engineered version of the ingredient. None of those pieces, by themselves, tells you how much to put on your own plate. That’s the situation we’re actually in with MOTS-c. Let’s break down what it is, how it’s thought to work, what to watch out for, and how you might reasonably decide what to do with all this.
First, what even is MOTS-c?
Most of the proteins in your body are built from instructions in your regular DNA, the stuff packed into the nucleus of your cells. MOTS-c is odd because it’s coded for by DNA sitting inside your mitochondria instead, the little energy-producing structures inside cells that most of us learned about in middle school as “the powerhouse of the cell.” A peptide is just a short chain of amino acids, smaller than a full protein, and MOTS-c appears to act less like a brick in a wall and more like a messenger, circulating through your blood and nudging things like insulin sensitivity, fat metabolism, and how your cells respond to stress.
That’s genuinely interesting biology. It is also, so far, mostly a story told through animal studies and a handful of early human observations. Calling it “well understood” right now would be overselling it.
How it’s supposed to work, and where the trail runs cold
The place everyone starts is the 2015 paper in Cell Metabolism, led by Changhan Lee, the one that put MOTS-c on the map in the first place. It’s solid science: the peptide activates something called AMPK (think of it as a kind of master energy switch in your cells) by acting on a pathway called the folate cycle, and treating mice with it stopped them from gaining weight on a high-fat diet and protected them from age-related and diet-related insulin resistance [M1].
Naturally, I went digging in that paper for a usable dose. Here’s where I kept hitting a wall: every dose in that study is a mouse dose, injected into mice, measured in milligrams per kilogram of mouse. You can’t take a mouse’s dose and just shrink or stretch it onto a human, the same way you can’t take your golden retriever’s flea medication dosage and scale it down for your cat by eyeballing the math. Metabolism differs, absorption differs, and a discovery study in animals was never built to answer “how much should a person inject.” Real biology. Not a transferable number. Dead end one.
What the exercise study actually showed (and didn’t)
Next stop: the 2021 Nature Communications paper from Joseph Reynolds and his team, the one that got MOTS-c nicknamed an “exercise mimetic.” In mice, it improved treadmill performance across young, middle-aged, and old animals, and it helped even when the mice started treatment late in life [M2]. The human piece of that paper is small: in ten young men, exercise raised the body’s own natural MOTS-c levels in muscle and blood [M2].
Here’s where it’s easy to get misled. That is not a dosing study. Nobody gave those ten men an injection of MOTS-c. Researchers just watched their own bodies produce more of it after a workout. It’s a bit like noticing your body sweats more when you exercise in the heat, that tells you something true about how your body responds, but it doesn’t tell you how many ounces of water to drink beforehand. Interesting clue about biology. No dose. Dead end two, though a useful one: it hints that MOTS-c release is tied to activity and probably comes in waves, not a flat, steady weekly amount.
The human study that comes closest, and still isn’t a dosing answer
The 2021 Scientific Reports trial led by Christina Dieli-Conwright is the most human-relevant thing I found, so I read it hoping hard for a signal. It followed 49 breast cancer survivors through sixteen weeks of supervised exercise and tracked their circulating MOTS-c. It rose significantly in the non-Hispanic White participants, but not in the Hispanic participants, and it only tracked with real metabolic improvement in the group that responded [M4].
That’s fascinating and also, once again, not a dosing study. It’s a marker study, measuring the body’s own output, and the big takeaway is that this response is not uniform person to person. In dosing terms, that’s humbling: if people’s own natural MOTS-c response varies this much, the notion of one fixed injected number being “correct” for everybody starts to look shaky before you even get to a trial. Strike three on finding a number, but the picture was sharpening, just not toward a chart.
The closest thing to a real dose, and why it still isn’t one
Then I found the one actual human therapeutic trial in this whole space. Except it isn’t a trial of MOTS-c. It’s a trial of an engineered cousin of it.
A company called CohBar built a modified analog they call CB4211 and tested it in people with obesity and fatty liver disease. In the Phase 1b portion, twenty people took part, eleven on the drug and nine on placebo, over four weeks. The company reported in 2021 that it was well tolerated with no serious adverse events. Compared to placebo, it produced statistically significant drops in the liver markers ALT (about 21 percent versus 4 percent) and AST (about 28 percent versus 11 percent), roughly a 6 percent drop in glucose, and a trend toward lower body weight [M5].
This is the closest anyone has gotten to a real human protocol, and I still can’t hand it to you as a dose, for good reasons. It’s a different molecule, an engineered variant with its own personality, not the MOTS-c sold in a research vial. It was small and built mainly to check safety, not to fine-tune a dose. And the program never turned into an approved drug, so there’s no settled, published human dose sitting on a shelf waiting to be borrowed. One promising small trial is a reason to keep researching a compound. It is not an instruction manual.
So where do those “5 to 10 mg per week” charts online actually come from?
By this point I’d read the real papers and come up empty-handed on an actual research-backed human dose. So where do those confident numbers come from, the ones you’ll see listing something like 5 to 10 mg a week, split into a few shots, run in cycles with a break?
The plain answer: they come from each other. They started as forum chatter and got copy-pasted onto vendor pages, where sitting next to a price tag makes them look official. They were never derived from a human trial testing whether those amounts actually work, because that trial hasn’t happened. A 2022 review in the International Journal of Molecular Sciences says the quiet part out loud: MOTS-c is the most recently discovered of the mitochondrial-derived peptides, the claimed benefits are broad, and the science is still mostly animal work with human data just beginning to trickle in [M3]. A number doesn’t earn the label “evidence-based” just because it’s been typed a thousand times.
What to watch for
None of this means MOTS-c is dangerous by definition, but it does mean you’re operating with a lot of missing information, and that changes what you should watch for.
Formal human safety data is thin, because no large completed trial has been published. People posting in forums mention things like injection-site irritation, fatigue, and occasional headaches, but without a control group there’s no way to know whether that’s the peptide, the injection itself, whatever it’s mixed in, or plain coincidence. The honest answer is that we don’t have a settled side-effect profile yet, and anyone telling you otherwise is guessing out loud with confidence they haven’t earned.
Quality control is the other real concern. In the US, MOTS-c isn’t FDA-approved, so selling it as a supplement or for human use sits in a legally murky spot. Research-chemical vendors aren’t required to verify purity, concentration, or sterility, and independent testing has repeatedly found peptide products on the market that are mislabeled. That’s a genuinely different risk category than buying a vial off a website with no accountability chain behind it.
How to decide
Here’s the honest conclusion from the whole chase, and it’s not the chart I set out to find.
There is no MOTS-c dose that “the research supports” in the way people mean when they ask that question. The research supports that MOTS-c is biologically active in cells and animals, that your body makes more of its own when you exercise, and that one engineered cousin of it looked safe and showed early promise in a tiny human trial. None of that hands you a milligram figure to draw into a syringe on your kitchen counter.
Which brings me to the only dosing advice I feel comfortable giving: this belongs in the hands of a licensed clinician, not a forum thread and not a vendor’s product page. A compound with no established human dose, real plausible metabolic effects, and a genuine interaction risk is exactly the situation where having a prescriber who can set and adjust your dose, and catch problems early, is the difference between a careful, monitored trial and a reckless guess. That’s the whole idea behind a supervised telehealth provider like FormBlends: same molecule the gray market ships you with a copy-pasted chart, but with an actual clinician watching and adjusting. That supervision is the piece a vendor page simply cannot offer, someone accountable for the number.
One low-tech thing that genuinely helps either way
If you do decide to go this route with a clinician, here’s a concrete tip I came away convinced of: keep a real written log.
MOTS-c is dosed by injection over multi-week cycles, and whatever effects it has are metabolic and slow to show up. That means your memory is a bad tool for tracking it. “I think it was working” isn’t data your clinician can use. Writing down each dose, the date, and any symptoms turns a vague impression into something readable at your next check-in. Some people just use a notebook. A logging tool such as the FormBlends tracker app does the same job, recording dose and symptoms over time. To be clear about what that is: it’s a dose-and-symptom logging tool, nothing more, not a prescription and not a checkout. The point was never the app itself. The point is that a written record beats a fuzzy guess, especially for something this under-studied, where every careful observation is worth more than usual.
That’s the full report. I went looking for a dose the research actually supports, and the truest thing I can hand you is that it doesn’t exist yet, along with the two things that genuinely reduce your risk in the meantime: put a clinician in the loop, and write everything down.
Questions I hear again and again
Is there a research-supported human dose for MOTS-c?
No. As of mid-2026 there’s no published dose-response study of plain MOTS-c in people, which is the kind of study you’d actually need to establish a real dose. The human-relevant research that does exist either measured the body’s own natural MOTS-c as a marker, or tested an engineered analog, and neither one produces a milligram figure you can draw into a syringe. A chart that gives you a confident human dose is reporting forum tradition, not a clinical finding.
Where do the “5 to 10 mg per week” MOTS-c protocols come from?
They come from peptide forums and vendor pages copying one another, not from human trials, because those trials haven’t been run. The numbers look official sitting next to a price, but no published study has actually tested those amounts in people. Treat a repeated forum number as folklore, not a recommendation.
What is CB4211, and why isn’t it a MOTS-c dosing guide?
CB4211 is an engineered analog of MOTS-c that CohBar tested in an early-phase trial for obesity and fatty liver disease. Its 2021 Phase 1b results reported it as well tolerated, with early drops in liver markers and glucose compared to placebo. It’s the closest thing to a real human protocol we have, but it’s a different molecule, the study was tiny and mostly checking safety, and the program never became an approved drug, so there’s no settled dose to inherit from it.
Does exercise raise MOTS-c, and does that tell me how much to inject?
Yes, exercise raises your body’s own MOTS-c, seen in young men and in a group of breast cancer survivors, though the response varied a lot from person to person. That’s interesting biology, but it’s not an injection study, so it gives you no figure for how much to use or when. If anything, the fact that natural response varies so much argues against one fixed dose being right for everybody.
Why does keeping a log matter for MOTS-c specifically?
Because MOTS-c is injected over multi-week cycles and any real effects show up slowly through metabolism, memory alone can’t tell you whether anything actually changed. Writing down each dose, the date, and any symptoms turns a vague feeling into a record your clinician can actually use at a check-in. For something this under-studied, a careful written note is worth more than a hunch.
What is MOTS-c and what does it actually do in the body?
MOTS-c is a small peptide coded for by mitochondrial DNA rather than the regular nuclear DNA most proteins come from, which is genuinely unusual. It behaves more like a hormone than a building block, circulating in the blood and appearing to influence insulin sensitivity, fat metabolism, and how cells handle stress. Most of what we know comes from animal studies plus a handful of early human observations, so calling it well-characterized would be getting ahead of the evidence.
Is MOTS-c legal to buy and use?
It depends a lot on where you live and how it’s sold. In the US, MOTS-c isn’t FDA-approved as a drug, so selling it as a supplement or for human use sits in a legally murky spot. Research-chemical vendors operate with essentially no oversight. Physician-supervised compounding pharmacies like FormBlends work inside a regulated framework, which is a meaningfully different setup than ordering a powder online with nobody accountable.
What side effects have been reported with MOTS-c?
Formal human safety data is thin, since no large clinical trial has been completed and published. People self-reporting in forums mention injection-site irritation, fatigue, and occasional headaches, but without a control group there’s no way to know if that’s the peptide, the injection process, the carrier, or just coincidence. The honest answer is that the side-effect profile in humans just isn’t established yet, and anyone claiming otherwise is guessing.
Where should I buy MOTS-c if I’m seriously considering it?
Quality control is the real issue. Research-chemical suppliers aren’t required to verify purity, concentration, or sterility, and independent testing keeps turning up mislabeled peptide products across the industry. If you’re going to use something injected, a compounding pharmacy under physician supervision at least gives you a chain of accountability. Grabbing the cheapest vial online is a genuinely different risk category, not just a cheaper choice.
References
- Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. AMPK activation via the folate cycle; prevented diet-induced weight gain and insulin resistance in mice; dosing reported on a mouse mg/kg basis; human plasma analyzed to confirm circulation. Cell Metabolism, 2015. https://pubmed.ncbi.nlm.nih.gov/25738459/
- Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Treadmill performance improved in mice given MOTS-c; exercise raised endogenous MOTS-c in 10 young men (observational, not a dosing study). Nature Communications, 2021. https://pubmed.ncbi.nlm.nih.gov/33473109/
- Mohtashami Z, et al. MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases. Review; literature dominated by preclinical work, human data still emerging. International Journal of Molecular Sciences, 2022.
- Dieli-Conwright CM, et al. Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors. Randomized human study (n=49); exercise significantly raised circulating MOTS-c in non-Hispanic White survivors but not Hispanic survivors; a marker study, not a dosing study. Scientific Reports, 2021.
- CohBar, Inc. CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 (an analog of MOTS-c) Under Development for NASH and Obesity. Phase 1b, 20 subjects (11 CB4211, 9 placebo), four weeks; well tolerated with no serious adverse events; ALT -21% vs -4%, AST -28% vs -11%, glucose -6% versus placebo, trend toward lower body weight; an analog trial, not an established MOTS-c dose. Press release, Aug 10, 2021.
